Docetaxel: a new active agent in the therapy of metastatic breast cancer

Bibliography

• MCPHERSON K, STEEL CM, DIXON JM: Breast cancer - epi-demiology, risk factors, and genetics. Br. Med. J. (1994) 309:1003–1006.
   PubMed Web of Science ®Google Scholar
• HARRIS JR, MORROW M, BONADONNA G: Cancer of thebreast. In: Cancer: Principles and Practice of Oncology (4th Edition). DeVita VT, Jr., Hellman S, Rosenberg SA (Eds.), Lip-pincott, Philadelphia (1993):1264–1332.
   Google Scholar
• HENDERSON IC: Chemotherapy for metastatic disease.In: Breast Diseases (4th Edition). Harris JR, Hellman S, Henderson IC, Kinne DW (Eds.), Lippincott, Philadelphia (1990:604–665.
   Google Scholar
• LEONARD RCF, RODGER A, DIXON JM: Metastatic breast cancer. Br. Med. J. (1994) 309:1501–1504.
   PubMed Web of Science ®Google Scholar
• MOURIDSEN HT: Systemic therapy of advanced breast cancer. Drugs (1992) 44 (Suppl. 4):17–28.
   Google Scholar
• MOOSA A, SCHIMPFF S, ROBINSON M: In: Comprehensive Textbook of Oncology. Williams & Wilkins, USA (1991).
   Google Scholar
• RUBENS RD: Therapy for metastatic breast cancer. Cum Opin. Oncol. (1994) 6:578–582.
   PubMedGoogle Scholar
• SAUNDERS C: Current management of breast cancer. Br.J. Hosp. Med. (1993) 50:588–593.
   PubMed Web of Science ®Google Scholar
• WANI MC, TAYLOR HL, WALL ME, COGGON P, MCPHAILAT: Plant antitumor agents. VI. The isolation and struc-ture of Taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J. Am. Chem. Soc. (1971) 93:2325–2337.
   Google Scholar
• COLIN M, GUENARD D, GUERITTE VOEGELEIN F, POTTER P: Taxol derivatives, their preparation and pharmaceu-tical compositions containing them. Rhone-Poulenc Santé. US4814470 granted 21 March 1989 (priority date July 17, 1986).
   Google Scholar
• ROWINSKY EK, DONEHOWER RC: The clinical pharma-cology and use of antimicrotubule agents in cancer che-motherapeutics. PharmacoL Then (1991) 52:35–84.
   PubMed Web of Science ®Google Scholar
• CORREIA JJ: Effects of antimitotic agents on tubulin nu-cleotide interactions. Pharmacol, Then (1991) 52:127–147.
   PubMed Web of Science ®Google Scholar
• DUSTIN P: Microtubules. Sci, Am. (1980) 243:66–76.
   Google Scholar
• OTTO AM, ZUMBE A, GIBSON L, KUBLER AM, JIMINEZ-DE-ASUA L: Cytoskeletal-disrupting drugs enhance ef-fect of growth factors and hormones on initiation of DNA synthesis. Proc. Natl. Acad. Sci, USA (1979) 76:6435–6438.
   PubMed Web of Science ®Google Scholar
• GUERITTE VOEGELEIN F, GUENARD D, LAVELLE F et al.:Relationship between the structure of taxol analogues and their antimitotic activity. J. Med. Chem. (1991) 34:992–998.
   PubMed Web of Science ®Google Scholar
• BISSERY MC, NOHYNEK G, SANDERINK GJ, LAVELLE F: Docetaxel (Taxotere): a review of preclinical and clini-cal experience. Part I: preclinical experience. Antican-cer Drugs (1995) 6:339–368.
   PubMed Web of Science ®Google Scholar
• BISSERY MC, GUENARD D, GUERITTE VOEGELEIN F, LAV-ELLE F: Experimental antitumour activity of Taxotere (RP 56976, NSC 628503), a taxol analogue. Cancer Res. (1991) 51:4845–4852.
   PubMed Web of Science ®Google Scholar
• BISSERY MC, RENARD A, ANDRE S et al.: Preclinical phar-macology and toxicology of Taxotere (RP 56976, NSC 628503). Ann. Oncol, (1992) 3:121–126.
   Google Scholar
• AAPRO MS, ZULIAN G, ALBERTO Petal.: Phase land phar-macokinetic study of RP 56976 in a new ethanol free formulation of Taxotere. Ann. OncoL (1992) 3 (Suppl. 5)53. Abstract 208.
   Google Scholar
• EXTRA JM, ROUSSEAU F, BRUNO R et al.: Phase land phar-macokinetic study of Taxotere (docetaxel) (RP 56976; NSC 628503) given as a short intravenous infusion. Cancer Res. (1993) 53:1037–1042.
   PubMed Web of Science ®Google Scholar
• BISSETT D, SETANOIANS A, CASSIDY J et al.: Phase I and pharmacokinetic study of Taxotere® (RP 56976) admin-istered as a 24-hour infusion. Cancer Res. (1993) 53:523–527.
   PubMed Web of Science ®Google Scholar
• BRUNO R, VERGNIOL JC, MONTAY G et al.: Clinical phar-macology of Taxotere (RP 56976) given as 1- to 2-hour infusion every 2–3 weeks. Proc. AACR (1992) 33. Abstract 1561.
   Google Scholar
• BRUNO R, HILLE D, THOMAS L, RIVA A, SHEINER LB: Population pharmacokinetics/pharmacodynamics of docetaxel (Taxotere) in Phase II studies. Proc. ASCO (1995) 14:457. Abstract.
   Google Scholar
• OULID-AISSA D, BRUNO R, LEBECQ A et al.: Taxotere safety in patients with impaired liver function. Proc. ASCO (1996) 15. Abstract 1508.
   Google Scholar
• BURRIS HA, IRVIN R, KUHN J et al.: Phase I clinical trial of Taxotere administered as either a 2-hour or 6-hour in- travenous infusion. J.OncoL (1993) 11:950–958.
   Google Scholar
• TOMIAK E, PICCART MJ, KERGER J et al.: Phase I study of docetaxel administered as a one hour intravenous infu- sion on a weekly basis.OncoL (1994) 12:1458–1467.
   Google Scholar
• PAZDUR R, NEWMAN RA, NEWMAN BM et al.: Phase I trialof Taxotere: five-day schedule. Natl. Cancer Inst. (1992) 84:1781–1788.
   Google Scholar
• PAZDUR R, KUDELKA A, KAVANAGH JJ, COHEN PR, RA-BER MN: The Taxoids: paclitaxel (Taxol®) and docetaxel (Taxotere®). Cancer Treat. Rev. (1993) 19:351–386.
   PubMed Web of Science ®Google Scholar
• HUDIS C, SEIDMAN AD, CROWN JPA et al.: Phase II and pharmacologic study of docetaxel as initial chemother- apy for metastatic breast cancer. J.OncoL (1996)14:58–65.
   Google Scholar
• TRUDEAU ME, EISENHAUER EA, HIGGINS BP et al.: Doce-taxel in patients with metastatic breast cancer: a Phase II study of the National Cancer Institute of Canada - Clinical Trials Group. J.OncoL (1996) 14:422–428.
   Google Scholar
• CHEVALLIER B, FUMOLEAU P, KERBRAT P et al.: Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a Phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer. J. Din. Oncol, (1995) 13:314–322.
   PubMed Web of Science ®Google Scholar
• DIERAS V, CHEVALLIER B, KERBRAT P et al.: A multicentrePhase II study of docetaxel 75 mg/n2 as first-line che-motherapy for patients with advanced breast cancer: report of the Clinical Screening Group of the EORTC. Br. J. Cancer (1996) 74:650–656.
   PubMed Web of Science ®Google Scholar
• FUMOLEAU P, CHEVALLIER B, KERBRAT P et al.: A multi-centre Phase II study of the efficacy and safety of doce-taxel as first-line treatment of advanced breast cancer: report of the Clinical Screening Group of the EORTC. Ann. OncoL (1996) 7:165–171.
   PubMed Web of Science ®Google Scholar
• Taxotere docetaxel. International Product Monograph (2nd Edition). RhOne-Poulenc Rorer (1996).
   Google Scholar
• TEN BOKKEL HUININK WW, PROVE AM, PICCART M et al.: A Phase II trial with docetaxel (Taxoterel in second line treatment with chemotherapy for advanced breast cancer. Ann. OncoL (1994) 5:527–532.
   Google Scholar
• FUMOLEAU P: Treatment of patients with liver metasta-ses. Anticancer Drugs (1996) 7 (Suppl. 2) :21–23.
   Google Scholar
• STEINER R, STEWART JF, CANTWELL BM et al.: Adriamycin alone or combined with vincristine in the treatment of advanced breast cancer. Eur, J. Cancer Din. OncoL (1983) 19:1553–1517.
   PubMedGoogle Scholar
• AHMANN DL, BISEL HF, EAGAN RT, EDMONSON JH, HAHN RG: Controlled evaluation of adriamycin (NSC-123127) in patients with disseminated breast cancer. Cancer Chemother, Rep. (1974) 58(6 Part 0:877–882.
   Google Scholar
• BRAMBILLA C, ROSSI A, BONFANTE V et al.: Phase II study of doxorubicin versus epirubicin in advanced breast cancer. Cancer Treat. Rep. (1986) 70:261–266.
   PubMedGoogle Scholar
• ROMITO S, GIOTTA F, MAGGI V et al.: 120-hr continuous infusion of 4-epidoxorubicin in untreated patients with advanced breast cancer. A pilot study. Ann. Oncol, (1992) 3 (Suppl. 5):87.
   Google Scholar
• BATIST G, AHLGREN P, PANASCI L et al.: Phase II study of liposomal doxorubicin (TLC-D99) in metastatic breast cancer. Proc. ASCO (1992) 11. Abstract A155.
   Google Scholar
• FRENCH EPIRUBICIN STUDY GROUP: A prospective ran-domized Phase III trial comparing combination che-motherapy with cyclophosphamide, fluorouracil, and either doxorubicin or epirubicin. Din. Oncol, (1988) 4:679–688.
   Google Scholar
• VOGEL CL, SMALLEY RV, RANEY M et al.: Randomized trial of cyclophosphamide, doxorubicin, and 5-fluorouracil alone or alternating with a "cycle active" non-cross-resistant combination in women with vis-ceral metastatic breast cancer: a Southeastern Cancer Study Group project. J. Cl/n. Oncol, (1984) 2:643–651.
   PubMed Web of Science ®Google Scholar
• SPIELMANN M, DORVAL T, TURPIN F et al.: Phase II trial of vinorelbine/doxorubicin as first-line therapy of ad-vanced breast cancer. J. Cl/n. Oncol, (1 9 9 4) 12 (9): 1764–1770.
   Google Scholar
• ITALIAN MULTICENTER BREAST STUDY WITH EPIRUBI-CIN: Phase III randomized study of fluorouracil, epiru-bicin, and cyclophosphamide vs. fluorouracil, doxorubicin, and cyclophosphamide in advanced breast cancer: an Italian multicentre trial. J. Din. Oncol, (1988) 6:976–982.
   Google Scholar
• AISNER J, WEINBERG V, PERLOFF M et al.: Chemotherapy vs. chemoimmunotherapy (CAF v CAFVP v CMF each ± MER) for metastatic carcinoma of the breast: a CALGB study. J. Cl/n. Oncol, (1987) 5:1523–1533.
   Google Scholar
• FRENCH EPIRUBICIN STUDY GROUP: A prospective ran-domized trial comparing epirubicin monochemother-apy to two fluorouracil, cyclophosphamide and epirubicin regimens differing in epirubicin dose in ad-vanced breast cancer. J. Cl/n. Oncol, (1991) 9:305–312.
   PubMed Web of Science ®Google Scholar
• GIANNAKAKIS T, SAMELIS G, TSIRYANNIS P et al.: Efficacy and toxicity of 5-fluorouracil epirubicin cyclophospha-mide (FEC) combination in metastatic breast cancer. Ann. Oncol, (1992) 3 (Suppl. 5):87. Abstract.
   Google Scholar
• CANELLOS GP, POCOCK SJ, TAYLOR SG et al.: Combina-tion chemotherapy for metastatic breast carcinoma. Prospective comparison of multiple drug therapy with L-phenylalanine mustard. Cancer (1976) 38:1882–1886.
   Google Scholar
• COCCONI G, BISAGUE G, BACCHI M et al.: Cisplatin and etoposide as first-line chemotherapy for metastatic breast carcinoma: a prospective randomized trial of the Italian Oncology Group for Clinical Research. J. Din. Oncol, (1991) 9:664–669.
   PubMed Web of Science ®Google Scholar
• CREECH RH, CATALANO RB, MASTRANGELO MJ et al.: Aneffective low-dose intermittent cyclophosphamide, methotrexate and 5-fluorouracil treatment regimen for metastatic breast cancer. Cancer (1975) 35:1101–1107.
   PubMed Web of Science ®Google Scholar
• MUSS HB, WHITE DR, COOPER R et al.: Combination che-motherapy in advanced breast cancer. A randomized trial comparing a three- vs. a five-drug program. Arch. Intern. Med. (1977) 137:1711–1714.
   Google Scholar
• FUMOLEAU P, DELGADO FM, DELOZIER T et al.: Phase IItrial of weekly intravenous vinorelbine in first-line ad-vanced breast cancer chemotherapy. J. Din. Oncol, (1993) 11:1245–1252.
   PubMed Web of Science ®Google Scholar
• GARCIA-CONDE J, LLUCH A, MARTIN Metal.: Phase II trialof weekly IV vinorelbine in first-line advanced breast cancer chemotherapy. Ann. Oncol, (1994) 5:854–857.
   Google Scholar
• FERRERO JM, WENDLING JL, HOCH M et al.:Mitoxantrone-vinorelbine as first-line chemotherapy in metastatic breast cancer: a pilot study. Proc. ASCO (1993) 12. Abstract A234.
   Google Scholar
• DIERAS V, PIERGA JY, EXTRA JM et al.: Results of a combi-nation of navelbine and fluorouracil in advanced breast cancer with a group sequential design. Ann. On-col. (1992) 3 (Suppl. 5):46.
   Google Scholar
• SCHORNAGEL JH, VAN DER VEGT S, VERWEIJ J et al.:Phase II study of edatrexate in chemotherapy-naive pa-tients with metastatic breast cancer. Ann. Oncol, (1992) 3:549–552.
   Google Scholar
• KOLARIC K, VUKAS D: Carboplatin activity in metastatic breast cancer - a Phase II trial. Eighth Mediterranean Con-gress on Chemotherapy. Athens, Greece (1992).
   Google Scholar
• TWELVES CJ, O'REILLY SM, COLEMAN RE et al.: Weekly epirubicin for breast cancer with liver metastases and abnormal liver biochemistry. Br. J. Cancer (1989) 60:938–941.
   Google Scholar
• TWELVES CJ, RICHARDS MA, SMITH P et al.: Epirubicin in breast cancer patients with liver metastases and abnor-mal liver biochemistry: initial weekly treatment fol-lowed by rescheduling and intensification. Ann. Oncol (1991) 2:663–666.
   PubMed Web of Science ®Google Scholar
• O'REILLY SM, COLEMAN RE, RUBENS RD: Phase II study of mitoxantrone for liver metastases from breast cancer. Cancer Chemother, Pharmacol, (1989) 25:73–74.
   PubMed Web of Science ®Google Scholar
• ZINSER JW, HORTOBAYAGI GN, BUZDAR AU, SMITH TL, FRASCHINI G: Clinical course of breast cancer patients with liver metastases. J. Cl/n. Oncol, (1987) 5:773–782.
   PubMed Web of Science ®Google Scholar
• INOUE K, OGAWA M, HORIKOSHI N et al.: Clinical feature and chemotherapy of breast cancer patients with liver metastases. J. Jpn, Soc. Cancer Then (1992) 27:646–653.
   Google Scholar
• ADACHI I, WATANABE T, TAKASHIMA S et al.: A late Phase II clinical trial of docetaxel (RP 56976) in patients with advanced or recurrent breast cancer. Int. J. Oncol, (1994) 5 (Suppl 404).
   Google Scholar
• ROWINSKY EK, EISENHAUER EA, CHAUNDHRY V, AR-BUCK SG, DONEHOWER RC: Clinical toxicities encoun-tered with paclitaxel (Taxol). Semin, Oncol. (1993) 20:1–15.
   PubMed Web of Science ®Google Scholar
• VERWEIJ J, CLAVEL M, CHEVALLIER B: Paclitaxel (Tax-ol®) and docetaxel (Taxotere): not simply two of a kind. Ann. Oncol, (1994) 5:495–505.
   PubMed Web of Science ®Google Scholar
• SEIDMAN AD: The emerging role of paclitaxel in breast cancer therapy. Cl/n. Cancer Res. (1995) 1:247–256.
   PubMed Web of Science ®Google Scholar
• CHEVALLIER B, KERBRAT P, DIERAS V et al.: Activity of Taxotere® (docetaxel) in liver metastasis of advanced breast cancer: analysis of 17 patients. Experience of the EORTC Clinical Screening Group. Breast Cancer Res. Treat. (1994) 32 (Suppl 34). Abstract 23.
   Google Scholar
• YAMASAKI S, OKINO T, KAN N et al.: Factors influencing the response and survival of patients with liver metas-tases from breast cancer receiving OK-432-combined adoptive immunotherapy. J. Cancer Res. Cl/n. Oncol, (1992) 118:157–162.
   PubMed Web of Science ®Google Scholar
• VALERO V, HOLMES FA, WALTERS RS et al.: Phase II trialof docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer. J. Din. Oncol, (1995) 13:2886–2894.
   PubMed Web of Science ®Google Scholar
• RAVDIN P, VALERO V, BURRIS H et al.: Phase II trial of do-cetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer. J. Clin. Oncol. (1995) 13:2879–2885.
   PubMed Web of Science ®Google Scholar
• AAPRO M, PUJADE LAURAINE E, LHOMME C etal.: Phase II study of Taxotere in ovarian cancer. An EORTC Clini-cal Screening Group study. Proc. ASCO (1993) 12:256. Ab-stract 809.
   Google Scholar
• CERNY T, KAPLAN S, PAVLIDIS N et al.: Docetaxel (Tax-otere®) is active in non-small-cell lung cancer: a Phase II trial of the EORTC Early Clinical Trials Group (ECTG). Br. J. Cancer (1994) 70:183–184.
   PubMedGoogle Scholar
• SULKES A, SMYTH J, SESSA C et al.: Docetaxel (Taxotere®) in advanced gastric cancer: results of a Phase II clinical trial. Br. J. Cancer (1994) 70:380–383.
   PubMed Web of Science ®Google Scholar
• VAN HOESEL QGCM, VERWEIJ J, CATIMEL G et al.: Phase II study with docetaxel (Taxotere®) in advanced soft tis-sue sarcomas of the adult. Ann. Oncol, (1994) 5:539–542.
   PubMed Web of Science ®Google Scholar
• CATIMEL G, VERWEIJ J, MATTIJSSEN V et al.: Docetaxel (Taxoteree): an active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck. Ann. OncoL (1994) 5:533–537.
   PubMed Web of Science ®Google Scholar
• SMYTH JF, SMITH IE, SESSA C et al.: Activity of docetaxel (Taxotere®) in small cell lung cancer. Eur, J. Cancer (1994) 30A:1058–1060.
   PubMed Web of Science ®Google Scholar
• ROWINSKY EK, GILBERT MR, MCGUIRE WP et al.: Se-quences of Taxol and cisplatin: a Phase I pharma- cologic study.OncoL (1991) 9:1692–1703.
   Google Scholar
• SCHELLENS JHM, MA J, PLANTING AST et al.: Pharmacoki-netics and WBC DNA adduct formation of cisplatin in the sequence docetaxel (Taxotere)/cisplatin and cis-platin/docetaxel in a Phase I/II study in solid tumor pa-tients. Ann. OncoL (1994) 5. Abstract 503.
   Google Scholar